MDGL.US Madrigal Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
427.39 USD
Close of Nov 15, 2026
353.54 615.00
Market cap
USD 9.93B
P/E
-
P/B
15.84x
ROE
-20.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MDGL.US undervalued?

Graham number

The Graham number of Madrigal Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Madrigal Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Madrigal Pharmaceuticals Inc yet.

Madrigal Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Full company profile